Yesterday, Amgen (AMGN) said that Aranesp failed in a large, randomized, double-blind, placebo-controlled, phase III study that was conducted in patients with chronic kidney disease (not requiring dialysis), anemia and type II diabetes. The study, referred to as the Trial to Reduce Cardiovascular Endpoints with Aranesp Therapy (TREAT), had two primary endpoints. The first evaluated time [...]

(AMGN) Amgen’s Kidney Drug Fails Phase III Study

Microsoft Jasper motherboard Xbox 360s are now in the shops. These have both a 65nm GPU and a 65nm CPU so they run less warm than the older motherboards. You can identify them because they are rated at a lower 12.1A instead of 14.2A. This should make them yet more reliable and finally consign RRoD [...]

OmniVision (OVTI) is a fabless OEM (an original equipment manufacturer who outsources chip fabrication) of image sensors and support circuitry used within handsets and applications in other mass markets. The Sunnyvale, CA firm is currently rated a Hold with a $15 target price. Shares have fallen from $24+ peak just about one year ago, now trading just over $12 per share. The shares have traded down over the last two months, but we are reiterating our Hold rating in view of uncertainties in consumer spending and possible market share losses in China. OmniVision has a strong position in the fast growing CMOS image sensor market and is particularly dominant in the camera phone market. All the top handset manufacturers have expressed interest in the BSI technology and the product will be incorporated into cell phones shipping in[More...]

Submitted By Optiondragon[More...]

Submitted By Optiondragon [More...]